| Autor: |
Dean Tantin, Thomas Ludwig, Rachel E. Factor, Reuben R. Cano, Dongju Park, Jinsuk Kang, Jessica Maddox, Karina Vázquez-Arreguín |
| Rok vydání: |
2023 |
| Popis: |
Supp. Figure S1 Differential metabolite levels in BRCA1 I26A compared to normal MEFs. Supp. Figure S2 Control immunofluorescence microscopy images using Oct1-deficient MEFs. Supp. Figure S3 Small increase in Oct1 proteins levels in MEFs with a C-terminal BRCA1 mutation. Supp. Figure S4 Equivalent infection rates in Oct1 and control CRISPR infection rates in BRCA1-I26A MEFs. Supp. Figure S5 Quality-control and validation of RNAseq. Supp. Figure S6 CRISPR-mediated Oct1 loss in either BRCA1-I26A MEFs or MCF-7 cells minimally affects HIF-1α and c-Myc levels. Supp. Figure S7 Equivalent infection rates in Oct1 and control CRISPR infection rates in MCF-7 cells. Supp. Figure S8 MG-132 treatment reveals ubiquitylated Oct1 bands in the presence of urea. Supp. Figure S9 O2 consumption rate (OCR) was assessed in MCF-7 cells transduced with either empty vector control (EV), or viruses expressing WT or K9/403R Oct1. Supp. Figure S10 Oct1 protein stability in WT and I26A MEFs. Supp. Figure S11 Immunoprecipitating in vitro ubiquitylation assay products with control rabbit IgG antibodies results in recovery of background ubiquitylation. Supp. Figure S12 The same as in Figure 6A except with individual datapoints (Supplemental Table S4) superimposed. Supp. Figure S13 Elevated Oct1 (Pou2f1) mRNA levels correlate with poor patient outcome in gastric but not breast cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
